Régis Bataille

Active 1981–2020

Also published as
Regis Bataille
87
Papers
21,709
Citations
80
h-index
87
i10-index

Citations

Citations per year for Régis Bataille1956: 1 citations1983: 1 citations1985: 3 citations1986: 3 citations1987: 2 citations1988: 2 citations1989: 8 citations1990: 26 citations1991: 40 citations1992: 60 citations1993: 54 citations1994: 64 citations1995: 82 citations1996: 72 citations1997: 97 citations1998: 121 citations1999: 123 citations2000: 164 citations2001: 197 citations2002: 244 citations2003: 326 citations2004: 280 citations2005: 262 citations2006: 253 citations2007: 264 citations2008: 179 citations2009: 220 citations2010: 199 citations2011: 205 citations2012: 169 citations2013: 148 citations2014: 121 citations2015: 126 citations2016: 109 citations2017: 89 citations2018: 82 citations2019: 269 citations2020: 295 citations2021: 269 citations2022: 175 citations2023: 78 citations2024: 147 citations2025: 42 citations2026: 2 citations1957–1982: no citations, so these years are not shown1984: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,880 citing papers, 31.5% of this breakdownFrance: 480 citing papers, 8% of this breakdownItaly: 376 citing papers, 6.3% of this breakdownGermany: 363 citing papers, 6.1% of this breakdownUnited Kingdom: 360 citing papers, 6% of this breakdownChina: 265 citing papers, 4.4% of this breakdownSpain: 223 citing papers, 3.7% of this breakdownCanada: 194 citing papers, 3.3% of this breakdownNetherlands: 183 citing papers, 3.1% of this breakdownJapan: 175 citing papers, 2.9% of this breakdownAustralia: 163 citing papers, 2.7% of this breakdownBelgium: 113 citing papers, 1.9% of this breakdown
0%31.5%Other 20.1%

Fields

  • Medicine72.4%
  • Biochemistry, Genetics and Molecular Biology18.2%
  • Immunology and Microbiology7.4%
  • Neuroscience0.4%
  • Computer Science0.2%
  • Dentistry0.2%
  • Other1.2%

Topics

  • Multiple Myeloma Research and Treatments17%
  • Protein Degradation and Inhibitors5.8%
  • Peptidase Inhibition and Analysis3.6%
  • Cytokine Signaling Pathways and Interactions2.5%
  • Chronic Lymphocytic Leukemia Research2.4%
  • Ubiquitin and proteasome pathways2.2%
  • Other66.5%

Coauthors

All papers

Open in search
  1. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stéphane Minvielle, Jean‐Luc Harousseau, Thierry Façon, Claire Mathiot - Blood 2007 cited by 905

  2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , C Anderson Kenneth, Michael Attal, Hervé Avet‐Loiseau, Ashraf Badros, Dalsu Baris, Bart Barlogie, Régis Bataille, Meral Beksaç, Andrew Belch, Dina Ben‐Yehuda, Bill Bensinger, P. Leif Bergsagel, Jenny Bird, Joan Bladé, Mario Boccadoro, Michèle Cavo, Asher Chanan‐Khan, Wen Ming Chen, Tony Child, James Chim, Wee Joo Chng, Ray Comenzo, John Crowley, William S. Dalton, Faith E. Davies, Cármino Antônio De Souza, Michel Delforge, Meletios Α. Dimopoulos, Angela Dispenzieri, Johannes Drach, Matthew T. Drake, Brian G.M. Durie, Hermann Einsele, Theirry Facon, Dorotea Fantl, Jean‐Paul Fermand, Rafaël Fonseca, Gösta Gahrton, Ramón García‐Sánz, Christina Gasparetto, Morie A. Gertz, John Gibson, Sergio Giralt, Hartmut Goldschmidt, Philip R. Greipp, Roman Hájek, Izhar Hardan, Parameswaran Hari, Jean‐Luc Harousseau, Hiroyuki Hata, Yutaka Hattori, Tom Heffner, Joy Ho, Vânia Hungria, Shinsuke Ida, Peter Jacob, Sundar Jagannath, Hans Erik Johnsen, Jian Hou, Douglas Joshua, Artur Jurczyszyn, Michio Kawano, Nicolaus Kröger, Shaji Kumar, Robert A. Kyle, Martha Q. Lacy, Juan José Lahuerta, Ola Landgren, Jacob P. Laubach, Jae Hoon Lee and 60 more - Leukemia 2011 cited by 721

  3. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

    Authors: , , , , , , , , , , , - New England Journal of Medicine 1996 cited by 2,571

  4. Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2003 cited by 974

  5. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors

    Authors: , , , , , - Blood 2001 cited by 281

  6. Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple Myeloma

    Authors: , , , , , , , - Cancer Research 2007 cited by 237

  7. Interleukin-6 is a growth factor for nonmalignant human plasmablasts

    Authors: , , - Blood 2001 cited by 201

  8. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells

    Authors: , , , , , , , - Blood 2002 cited by 430

  9. Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 369

  10. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

    Authors: , , , , , , , - Blood 2002 cited by 357

  11. Genetics and Cytogenetics of Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , - Cancer Research 2004 cited by 686

  12. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival

    Authors: , , , , , , , , - Leukemia 2005 cited by 338

  13. Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody

    Authors: , , , , , , , , - New England Journal of Medicine 1994 cited by 334

  14. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype

    Authors: , , , , , , , , , , , , , , , , - Kidney International 2010 cited by 270

  15. Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

    Authors: , , , , , , , , , , , - Blood 2002 cited by 266

  16. ABT-737 is highly effective against molecular subgroups of multiple myeloma

    Authors: , , , , , , , , , , , - Blood 2011 cited by 124

  17. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

    Authors: , , , , , , , - Blood 1989 cited by 755

  18. Interleukin-6 in human multiple myeloma

    Authors: , , , - Blood 1995 cited by 535

  19. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

    Authors: , , , , - Blood 2001 cited by 413

  20. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique

    Authors: , , , , , , , , , - Blood 2001 cited by 185

  21. Constitutive production of interleukin‐6 and immunologic features in cardiac myxomas

    Authors: , , , , , - Arthritis & Rheumatism 1990 cited by 170

  22. CD28, a marker associated with tumoral expansion in multiple myeloma.

    Authors: , , , , , , , , , , - 1998 cited by 105

  23. High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo

    Authors: , , , , , - European Journal of Immunology 1992 cited by 103

  24. A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myeloma

    Authors: , , , , , - British Journal of Haematology 2000 cited by 88